Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: a population-based cohort study. Liver Int. 2022;42(4):820–828. doi:10.1111/liv.15195
   PubMed Web of Science ®Google Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: a Cross-Sectional Retrospective Study. J Clin Med. 2021;10(2):346. doi:10.3390/jcm10020346
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD. Clin Mol Hepatol. 2023;29(Suppl):S17–S31. doi:10.3350/cmh.2022.0367
   PubMedGoogle Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Nassir F, Ibdah JA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22(46):10084–10092. doi:10.3748/wjg.v22.i46.10084
   PubMed Web of Science ®Google Scholar
• Colak Y, Yesil A, Mutlu HH, et al. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointestin Liver Dis. 2014;23(3):311–319. doi:10.15403/jgld.2014.1121.233.yck
   PubMed Web of Science ®Google Scholar
• Chalasani N, Vuppalanchi R, Rinella M, et al. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47(12):1639–1651. doi:10.1111/apt.14674
   PubMed Web of Science ®Google Scholar
• Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895–902. doi:10.1016/j.metabol.2014.04.003
   PubMed Web of Science ®Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–735. doi:10.1053/j.gastro.2013.11.049
   PubMed Web of Science ®Google Scholar
• Ferré P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update1. Biochem J. 2021;478(20):3723–3739. doi:10.1042/BCJ20210071
   PubMed Web of Science ®Google Scholar
• Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C. Novel insights into ChREBP regulation and function. Trends Endocrinol Metab. 2013;24(5):257–268. doi:10.1016/j.tem.2013.01.003
   PubMed Web of Science ®Google Scholar
• Dentin R, Pégorier JP, Benhamed F, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279(19):20314–20326. doi:10.1074/jbc.M312475200
   PubMed Web of Science ®Google Scholar
• Kemper JK, Choi SE, Kim DH. Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism. Vitam Horm. 2013;91:385–404.
   PubMed Web of Science ®Google Scholar
• Wang RH, Li C, Deng CX. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci. 2010;6(7):682–690. doi:10.7150/ijbs.6.682
   PubMed Web of Science ®Google Scholar
• Ponugoti B, Kim DH, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010;285(44):33959–33970. doi:10.1074/jbc.M110.122978
   PubMed Web of Science ®Google Scholar
• Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest. 2010;120(12):4316–4331. doi:10.1172/JCI41624
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi:10.1136/gutjnl-2019-319664
   PubMed Web of Science ®Google Scholar
• Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006;68(1):159–191. doi:10.1146/annurev.physiol.68.033104.152158
   PubMedGoogle Scholar
• Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819–2830. doi:10.1101/gad.844900
   PubMed Web of Science ®Google Scholar
• Walker AK, Yang F, Jiang K, et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010;24(13):1403–1417. doi:10.1101/gad.1901210
   PubMed Web of Science ®Google Scholar
• Moore MP, Cunningham RP, Meers GM, et al. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology. 2022;76(5):1452–1465. doi:10.1002/hep.32324
   PubMed Web of Science ®Google Scholar
• Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813(7):1269–1278. doi:10.1016/j.bbamcr.2010.09.019
   PubMed Web of Science ®Google Scholar
• Montagner A, Polizzi A, Fouché E, et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016;65(7):1202–1214. doi:10.1136/gutjnl-2015-310798
   PubMed Web of Science ®Google Scholar
• Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327–338. doi:10.1016/j.cmet.2009.02.006
   PubMed Web of Science ®Google Scholar
• Kim HS, Xiao C, Wang RH, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 2010;12(3):224–236. doi:10.1016/j.cmet.2010.06.009
   PubMed Web of Science ®Google Scholar
• Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2007;31(1 Suppl):S61–6. doi:10.1111/j.1530-0277.2006.00288.x
   PubMedGoogle Scholar
• St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397–408. doi:10.1016/j.cell.2006.09.024
   PubMed Web of Science ®Google Scholar
• Klotz LO, Sánchez-Ramos C, Prieto-Arroyo I, Urbánek P, Steinbrenner H, Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol. 2015;6:51–72. doi:10.1016/j.redox.2015.06.019
   PubMed Web of Science ®Google Scholar
• Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793–9798. doi:10.1073/pnas.0802917105
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang J, Zheng Y, et al. NAD(+) improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1/PGC-1α pathway. J Neuroinflammation. 2021;18(1):207. doi:10.1186/s12974-021-02250-8
   PubMed Web of Science ®Google Scholar
• Hori YS, Kuno A, Hosoda R, Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013;8(9):e73875. doi:10.1371/journal.pone.0073875
   PubMed Web of Science ®Google Scholar
• Takizawa Y, Kosuge Y, Awaji H, et al. Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIRT1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells. Br J Nutr. 2013;110(12):2150–2155. doi:10.1017/S0007114513001670
   PubMed Web of Science ®Google Scholar
• Carrizzo A, Forte M, Damato A, et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol. 2013;61:215–226. doi:10.1016/j.fct.2013.07.021
   PubMed Web of Science ®Google Scholar
• Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622. doi:10.1016/j.cmet.2011.10.002
   PubMed Web of Science ®Google Scholar
• Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150(8):1769–1777. doi:10.1053/j.gastro.2016.02.066
   PubMed Web of Science ®Google Scholar
• Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107(1):7–11. doi:10.1172/JCI11830
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25(10):1939–1948. doi:10.1016/j.cellsig.2013.06.007
   PubMed Web of Science ®Google Scholar
• Zhang R, Chen HZ, Liu JJ, et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem. 2010;285(10):7097–7110. doi:10.1074/jbc.M109.038604
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–944. doi:10.1111/jgh.13264
   PubMed Web of Science ®Google Scholar
• Fujii H, Kawada N, Jsg-Nafld JSGON. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020;21(11):3863. doi:10.3390/ijms21113863
   PubMed Web of Science ®Google Scholar
• Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250–259. doi:10.2337/db08-0392
   PubMed Web of Science ®Google Scholar
• Li Y, Wong K, Walsh K, Gao B, Zang M. Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. J Biol Chem. 2013;288(15):10490–10504. doi:10.1074/jbc.M112.429852
   PubMed Web of Science ®Google Scholar
• Knight CM, Gutierrez-Juarez R, Lam TK, et al. Mediobasal hypothalamic SIRT1 is essential for resveratrol’s effects on insulin action in rats. Diabetes. 2011;60(11):2691–2700. doi:10.2337/db10-0987
   PubMed Web of Science ®Google Scholar
• Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes. 2009;58(2):344–351. doi:10.2337/db07-1795
   PubMed Web of Science ®Google Scholar
• Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem. 2006;281(52):39915–39924. doi:10.1074/jbc.M607215200
   PubMed Web of Science ®Google Scholar
• Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103. doi:10.1016/j.cca.2013.05.021
   PubMed Web of Science ®Google Scholar
• Choi SE, Fu T, Seok S, et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell. 2013;12(6):1062–1072. doi:10.1111/acel.12135
   PubMed Web of Science ®Google Scholar
• Wang L, Sun M, Cao Y, et al. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Arch Biochem Biophys. 2020;695:108642. doi:10.1016/j.abb.2020.108642
   PubMed Web of Science ®Google Scholar
• Ding J, Li M, Wan X, et al. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep. 2015;5:13729. doi:10.1038/srep13729
   PubMed Web of Science ®Google Scholar
• Shan W, Gao L, Zeng W, et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease. Cell Death Dis. 2015;6(7):e1833. doi:10.1038/cddis.2015.196
   PubMedGoogle Scholar
• Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58(4):785–791. doi:10.1016/j.jhep.2012.11.042
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen X, Gao J, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. FASEB J. 2019;33(10):11411–11419. doi:10.1096/fj.201900643RRR
   PubMed Web of Science ®Google Scholar
• Zhang E, Yin S, Zhao C, Fan L, Hu H. Involvement of activation of PLIN5-Sirt1 axis in protective effect of glycycoumarin on hepatic lipotoxicity. Biochem Biophys Res Commun. 2020;528(1):7–13. doi:10.1016/j.bbrc.2020.05.072
   PubMed Web of Science ®Google Scholar
• Gui W, Zhu Y, Sun S, et al. Knockdown of insulin-like growth factor 2 gene disrupts mitochondrial functions in the liver. J Mol Cell Biol. 2021;13(8):543–555. doi:10.1093/jmcb/mjab030
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang SY, Qi-Li FR, et al. Administration of isoliquiritigenin prevents nonalcoholic fatty liver disease through a novel IQGAP2-CREB-SIRT1 axis. Phytother Res. 2021;35(7):3898–3915. doi:10.1002/ptr.7101
   PubMed Web of Science ®Google Scholar
• Geng C, Zhang Y, Gao Y, et al. Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice. Biochem Biophys Res Commun. 2016;471(4):444–449. doi:10.1016/j.bbrc.2016.02.059
   PubMed Web of Science ®Google Scholar
• Lee DE, Lee SJ, Kim SJ, Lee HS, Kwon OS. Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of O-GlcNAcylation. Nutrients. 2019;11(11):2702. doi:10.3390/nu11112702
   PubMed Web of Science ®Google Scholar
• Zhu W, Chen S, Li Z, et al. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr Metab. 2014;11(1):35. doi:10.1186/1743-7075-11-35
   Google Scholar
• Hajighasem A, Farzanegi P, Mazaheri Z, Naghizadeh M, Salehi G. Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver. PeerJ. 2018;6:e5522. doi:10.7717/peerj.5522
   PubMed Web of Science ®Google Scholar
• Tian Y, Ma J, Wang W, et al. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 2016;422(1–2):75–84. doi:10.1007/s11010-016-2807-x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen ML, Zhou Y, et al. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res. 2015;59(8):1443–1457. doi:10.1002/mnfr.201500016
   PubMed Web of Science ®Google Scholar
• Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun. 2009;380(3):644–649. doi:10.1016/j.bbrc.2009.01.163
   PubMed Web of Science ®Google Scholar
• Andrade JM, Paraíso AF, de Oliveira MV, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30(7–8):915–919. doi:10.1016/j.nut.2013.11.016
   PubMed Web of Science ®Google Scholar
• Xu K, Liu S, Zhao X, et al. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomed Pharmacother. 2019;110:844–849. doi:10.1016/j.biopha.2018.12.039
   PubMed Web of Science ®Google Scholar
• Santamarina AB, Oliveira JL, Silva FP, et al. Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS One. 2015;10(11):e0141227. doi:10.1371/journal.pone.0141227
   PubMed Web of Science ®Google Scholar
• Li S, Qian Q, Ying N, et al. Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice. Front Pharmacol. 2020;11:560905. doi:10.3389/fphar.2020.560905
   PubMed Web of Science ®Google Scholar
• Zeng W, Shan W, Gao L, et al. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Sci Rep. 2015;5(1):16013. doi:10.1038/srep16013
   PubMedGoogle Scholar
• Liou CJ, Lee YK, Ting NC, et al. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. Cells. 2019;8(5):447. doi:10.3390/cells8050447
   PubMed Web of Science ®Google Scholar
• Na AY, Yang EJ, Jeon JM, Ki SH, Song KS, Lee S. Protective Effect of Isoliquiritigenin against Ethanol-Induced Hepatic Steatosis by Regulating the SIRT1-AMPK Pathway. Toxicol Res. 2018;34(1):23–29. doi:10.5487/TR.2018.34.1.023
   PubMed Web of Science ®Google Scholar
• Liou CJ, Wu SJ, Shen SC, Chen LC, Chen YL, Huang WC. Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice. Cell Biosci. 2020;10:114. doi:10.1186/s13578-020-00477-1
   PubMed Web of Science ®Google Scholar
• Peng Z, Li X, Xing D, et al. Nobiletin alleviates palmitic acid‑induced NLRP3 inflammasome activation in a sirtuin 1‑dependent manner in AML‑12 cells. Mol Med Rep. 2018;18(6):5815–5822. doi:10.3892/mmr.2018.9615
   PubMed Web of Science ®Google Scholar
• Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem Toxicol. 2013;52:53–60. doi:10.1016/j.fct.2012.10.030
   PubMed Web of Science ®Google Scholar
• Peng J, Li Q, Li K, et al. Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: involvement of Akt Signaling and SIRT1. J Diabetes Res. 2017;2017:3417306. doi:10.1155/2017/3417306
   PubMed Web of Science ®Google Scholar
• Salomone F, Barbagallo I, Godos J, et al. Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. Nutrients. 2017;9(10):1086. doi:10.3390/nu9101086
   PubMed Web of Science ®Google Scholar
• Wu SJ, Huang WC, Yu MC, et al. Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem. 2021;91:108602. doi:10.1016/j.jnutbio.2021.108602
   PubMed Web of Science ®Google Scholar
• Xu H, Chen GF, Ma YS, et al. Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis. Front Pharmacol. 2020;11:216. doi:10.3389/fphar.2020.00216
   PubMed Web of Science ®Google Scholar
• Shan MY, Dai Y, Ren XD, et al. Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. J Integr Med. 2021;19(6):545–554. doi:10.1016/j.joim.2021.09.003
   PubMedGoogle Scholar
• Zheng Y, Liu T, Wang Z, Xu Y, Zhang Q, Luo D. Low molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice. Int J Biol Macromol. 2018;112:929–936. doi:10.1016/j.ijbiomac.2018.02.072
   PubMed Web of Science ®Google Scholar
• Wang K, Cao P, Wang H, et al. Chronic administration of Angelica sinensis polysaccharide effectively improves fatty liver and glucose homeostasis in high-fat diet-fed mice. Sci Rep. 2016;6(1):26229. doi:10.1038/srep26229
   PubMedGoogle Scholar
• Jia L, Li W, Li J, et al. Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity. Sci Rep. 2016;6(1):36209. doi:10.1038/srep36209
   PubMedGoogle Scholar
• Chyau CC, Wang HF, Zhang WJ, et al. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway. Int J Mol Sci. 2020;21(1):360. doi:10.3390/ijms21010360
   PubMed Web of Science ®Google Scholar
• Chen GC, Su HM, Lin YS, Tsou PY, Chyuan JH, Chao PM. A conjugated fatty acid present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD(+)/NADH ratio and activating PPARα, AMPK and SIRT1 signaling pathway. J Nutr Biochem. 2016;33:28–35. doi:10.1016/j.jnutbio.2016.03.009
   PubMed Web of Science ®Google Scholar
• Huang Q, Wang T, Yang L, Wang HY. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK. Int J Mol Sci. 2017;18(5):1063. doi:10.3390/ijms18051063
   PubMed Web of Science ®Google Scholar
• Cheng B, Gao W, Wu X, et al. Ginsenoside Rg2 Ameliorates High-Fat Diet-Induced Metabolic Disease through SIRT1. J Agric Food Chem. 2020;68(14):4215–4226. doi:10.1021/acs.jafc.0c00833
   PubMed Web of Science ®Google Scholar
• Yao H, Tao X, Xu L, et al. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway. Pharmacol Res. 2018;131:51–60. doi:10.1016/j.phrs.2018.03.017
   PubMed Web of Science ®Google Scholar
• Han X, Cui ZY, Song J, et al. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact. 2019;311:108794. doi:10.1016/j.cbi.2019.108794
   PubMed Web of Science ®Google Scholar
• Zhou K, Chen J, Wu J, et al. Atractylenolide III ameliorates cerebral ischemic injury and neuroinflammation associated with inhibiting JAK2/STAT3/Drp1-dependent mitochondrial fission in microglia. Phytomedicine. 2019;59:152922. doi:10.1016/j.phymed.2019.152922
   PubMed Web of Science ®Google Scholar
• Li Q, Tan JX, He Y, et al. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway. Int J Biol Sci. 2022;18(4):1594–1611. doi:10.7150/ijbs.68873
   PubMed Web of Science ®Google Scholar
• Cheng H, Xu N, Zhao W, et al. (-)-Epicatechin regulates blood lipids and attenuates hepatic steatosis in rats fed high-fat diet. Mol Nutr Food Res. 2017;61(11). doi:10.1002/mnfr.201700303
   Web of Science ®Google Scholar
• Li J, Liu M, Yu H, et al. Mangiferin Improves Hepatic Lipid Metabolism Mainly Through Its Metabolite-Norathyriol by Modulating SIRT-1/AMPK/SREBP-1c Signaling. Front Pharmacol. 2018;9:201. doi:10.3389/fphar.2018.00201
   PubMed Web of Science ®Google Scholar
• Su W, Zhang C, Chen F, et al. Purple sweet potato color protects against hepatocyte apoptosis through Sirt1 activation in high-fat-diet-treated mice. Food Nutr Res. 2020;64.
   Web of Science ®Google Scholar
• Tavares TB, Santos IB, de Bem GF, et al. Therapeutic effects of açaí seed extract on hepatic steatosis in high-fat diet-induced obesity in male mice: a comparative effect with rosuvastatin. J Pharm Pharmacol. 2020;72(12):1921–1932. doi:10.1111/jphp.13356
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang XH, Ebersole B, Ribnicky D, Wang ZQ. Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice. Sci Rep. 2013;3(1):3142. doi:10.1038/srep03142
   PubMedGoogle Scholar
• Wang JH, Hwang SJ, Lim DW, Son CG. Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model. Cells. 2021;11(1):23. doi:10.3390/cells11010023
   PubMed Web of Science ®Google Scholar
• Kim YJ, Choi JY, Ryu R, et al. Platycodon grandiflorus Root Extract Attenuates Body Fat Mass, Hepatic Steatosis and Insulin Resistance through the Interplay between the Liver and Adipose Tissue. Nutrients. 2016;8(9):532. doi:10.3390/nu8090532
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ramiro I, Vauzour D, Minihane AM. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proc Nutr Soc. 2016;75(1):47–60. doi:10.1017/S0029665115004218
   PubMed Web of Science ®Google Scholar
• Yarru LP, Settivari RS, Gowda NK, Antoniou E, Ledoux DR, Rottinghaus GE. Effects of turmeric (Curcuma longa) on the expression of hepatic genes associated with biotransformation, antioxidant, and immune systems in broiler chicks fed aflatoxin. Poult Sci. 2009;88(12):2620–2627. doi:10.3382/ps.2009-00204
   PubMed Web of Science ®Google Scholar
• Meng X, Zhou J, Zhao CN, Gan RY, Li HB. Health Benefits and Molecular Mechanisms of Resveratrol: a Narrative Review. Foods. 2020;9(3):340. doi:10.3390/foods9030340
   PubMed Web of Science ®Google Scholar
• Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: a Randomized Controlled Clinical Trial. J Am Coll Nutr. 2018;37(3):223–233. doi:10.1080/07315724.2017.1392264
   PubMed Web of Science ®Google Scholar
• Saeed M, Naveed M, Arif M, et al. Green tea (Camellia sinensis) and l-theanine: medicinal values and beneficial applications in humans-A comprehensive review. Biomed Pharmacother. 2017;95:1260–1275. doi:10.1016/j.biopha.2017.09.024
   PubMed Web of Science ®Google Scholar
• Torres LF, Cogliati B, Otton R. Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194 Expression in a High-Fat Diet Mouse Model. Oxid Med Cell Longev. 2019;2019:4168380. doi:10.1155/2019/4168380
   PubMed Web of Science ®Google Scholar
• Xiao J, Ho CT, Liong EC, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. 2014;53(1):187–199. doi:10.1007/s00394-013-0516-8
   PubMed Web of Science ®Google Scholar
• Ding C, Zhao Y, Shi X, et al. New insights into salvianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci Rep. 2016;6(1):28734. doi:10.1038/srep28734
   PubMed Web of Science ®Google Scholar
• Park MY, Mun ST. Dietary carnosic acid suppresses hepatic steatosis formation via regulation of hepatic fatty acid metabolism in high-fat diet-fed mice. Nutr Res Pract. 2013;7(4):294–301. doi:10.4162/nrp.2013.7.4.294
   PubMed Web of Science ®Google Scholar
• Sahu R, Goswami S, Narahari Sastry G, Rawal RK. The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: current and Future Perspectives. Chem Biodivers. 2023;20(2):e202201029. doi:10.1002/cbdv.202201029
   PubMed Web of Science ®Google Scholar
• Lemmens KJ, van de Wier B, Koek GH, et al. The flavonoid monoHER promotes the adaption to oxidative stress during the onset of NAFLD. Biochem Biophys Res Commun. 2015;456(1):179–182. doi:10.1016/j.bbrc.2014.11.055
   PubMedGoogle Scholar
• Chen M, Zhu J, Kang J, et al. Exploration in the Mechanism of Action of Licorice by Network Pharmacology. Molecules. 2019;24(16):2959. doi:10.3390/molecules24162959
   PubMed Web of Science ®Google Scholar
• Huang WC, Chang WT, Wu SJ, Xu PY, Ting NC, Liou CJ. Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures. Mol Nutr Food Res. 2013;57(10):1803–1813. doi:10.1002/mnfr.201300001
   PubMed Web of Science ®Google Scholar
• Roslan J, Giribabu N, Karim K, Salleh N. Quercetin ameliorates oxidative stress, inflammation and apoptosis in the heart of streptozotocin-nicotinamide-induced adult male diabetic rats. Biomed Pharmacother. 2017;86:570–582. doi:10.1016/j.biopha.2016.12.044
   PubMed Web of Science ®Google Scholar
• Lu ML, Xiang XH, Xia SH. Potential Signaling Pathways Involved in the Clinical Application of Oxymatrine. Phytother Res. 2016;30(7):1104–1112. doi:10.1002/ptr.5632
   PubMed Web of Science ®Google Scholar
• Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015;13(1):24. doi:10.1186/s12967-015-0383-6
   PubMedGoogle Scholar
• Lü JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009;7(3):293–302. doi:10.2174/157016109788340767
   PubMed Web of Science ®Google Scholar
• Prince PD, Fischerman L, Toblli JE, Fraga CG, Galleano M. LPS-induced renal inflammation is prevented by (-)-epicatechin in rats. Redox Biol. 2017;11:342–349. doi:10.1016/j.redox.2016.12.023
   PubMed Web of Science ®Google Scholar
• Li XX, Lu XY, Zhang SJ, et al. Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed Pharmacother. 2019;111:68–75. doi:10.1016/j.biopha.2018.12.019
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang ZF, Zheng GH, et al. The Inhibitory Effects of Purple Sweet Potato Color on Hepatic Inflammation Is Associated with Restoration of NAD⁺ Levels and Attenuation of NLRP3 Inflammasome Activation in High-Fat-Diet-Treated Mice. Molecules. 2017;22(8):1315. doi:10.3390/molecules22081315
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci. 2017;13(7):852–867. doi:10.7150/ijbs.19370
   PubMed Web of Science ®Google Scholar
• Tarantino G, Balsano C, Santini SJ, et al. It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them. Int J Mol Sci. 2021;22(24):13424. doi:10.3390/ijms222413424
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47(3):226–232. doi:10.1016/j.dld.2014.11.015
   PubMedGoogle Scholar
• Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–843. doi:10.1016/j.nutres.2014.09.005
   PubMed Web of Science ®Google Scholar
• Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456–464. doi:10.3109/00365521.2015.1107620
   PubMed Web of Science ®Google Scholar
• Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092–103.e1–6. doi:10.1016/j.cgh.2014.02.024
   Web of Science ®Google Scholar
• Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675–690. doi:10.1016/j.cmet.2012.04.003
   PubMed Web of Science ®Google Scholar
• Chakrabarti P, English T, Karki S, et al. SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res. 2011;52(9):1693–1701. doi:10.1194/jlr.M014647
   PubMed Web of Science ®Google Scholar